Erectile dysfunction (ED) remains one of the most prevalent male health concerns worldwide, significantly affecting quality of life for patients and their partners. While phosphodiesterase type 5 inhibitors (PDE5i) and intracavernosal therapies are effective for many, a substantial subset of men — particularly those with diabetes mellitus or post-prostatectomy nerve injury — fail to achieve satisfactory outcomes. This has driven the search for regenerative solutions.
Stem cell therapy (SCT) has emerged as a promising strategy aimed not merely at symptomatic relief but at restoring erectile function by repairing vascular, neural, and smooth muscle integrity. Our systematic review and meta-analysis sought to consolidate clinical trial evidence and provide a clearer picture of SCT’s efficacy in ED.
2. What We Found
From over 2,000 records screened, 11 clinical trials were included in the review, with six eligible for quantitative meta-analysis. Across studies, most reported meaningful improvements in erectile function following intracavernosal stem cell injections.
2.1. Questionnaire-based outcomes
- International Index of Erectile Function (IIEF-5, IIEF-EF) scores showed large effect sizes at six months, suggesting clinically meaningful improvements.
- Erectile Hardness Score (EHS) also improved significantly, reinforcing functional benefit.
- Peak systolic velocity (PSV) demonstrated a consistent increase, indicating improved penile hemodynamics.
- End-diastolic velocity (EDV) showed modest short-term gains but no sustained difference at 6 months.
3. Beyond the Numbers – Critical Insights:
While our pooled results support SCT’s potential, important caveats remain:
- Durability of effect: Several trials reported a decline in benefit beyond 6–12 months. This suggests that stem cell activity may be transient, driven largely by paracrine signaling rather than durable engraftment. Repeat dosing or adjunctive strategies may be necessary for sustained results.
- Patient subgroups:
- Diabetic ED: Improvements were observed, but attenuation over time reflects the advanced fibrosis and microvascular disease common in this group.
- Post-prostatectomy ED: SCT may offer neurotrophic and anti-inflammatory benefits, but studies remain small. These findings highlight the need to tailor therapy based on etiology.
- Heterogeneity of trials: Considerable variation existed in cell source (bone marrow, adipose, umbilical cord, Wharton’s Jelly, oral mucosa), dose, and administration protocols. Without standardization, direct comparisons are difficult.
- Trial limitations: Most studies were small, single-arm, or open-label, raising concerns about placebo effects and limiting generalizability. Only one randomized controlled trial has been published to date.
Stem cell therapy for ED represents a promising frontier in andrology, shifting the paradigm from symptomatic management to regenerative restoration. However, before SCT can move into routine clinical practice, we need:
- Larger, multicenter randomized controlled trials with longer follow-up (≥24 months)
- Standardized protocols for cell preparation, dose, and delivery.
- Studies exploring repeated dosing or combination strategies (e.g., with low-intensity shockwave therapy).
- Long-term safety assessments to address rare but serious risks such as fibrosis or tumorigenesis.
Our findings support SCT as a safe and potentially effective short-term treatment for ED, with consistent improvements in erectile function scores and penile hemodynamics. Yet, whether stem cell therapy is a true reality or remains a promise depends on the outcomes of ongoing and future well-designed clinical trials. By synthesizing the evidence to date, we aim to encourage further scientific rigor and collaborative research to translate stem cell therapy into a reliable therapeutic option for men with refractory ED.
Written by: Samet Senel, Ahmet Halil Sevinc, Huseyin Gultekin, Abduvaliyev Jaxongir Ravshanbekovich, Huseyin Besiroglu, Murat Dursun, and Ates Kadioglu
Istanbul Faculty of Medicine, Department of Urology, Section of Andrology, Istanbul, Türkiye
Read the Abstract